Co-occurrence of chronic myeloid leukemia with chronic lymphocytic leukemia: a report of two cases

被引：6

作者：

Boddu, Prajwal ^{[1
]}

Gibbons, Jamie ^{[1
]}

Burger, Jan ^{[1
]}

Sivina, Mariela ^{[1
]}

Thakral, Beenu ^{[2
]}

Kanagal-Shamanna, Rashmi ^{[2
]}

Ferrajoli, Alessandra ^{[1
]}

机构：

[1] UT MD Anderson Canc Ctr, Dept Leukemia, Houston, TX USA

[2] UT MD Anderson Canc Ctr, Dept Hematopathol, Houston, TX USA

来源：

LEUKEMIA & LYMPHOMA | 2019年 / 60卷 / 06期

关键词：

DASATINIB; IMATINIB; THERAPY;

D O I：

10.1080/10428194.2018.1547902

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：1568 / 1571

页数：4

共 22 条

[1] The potential for dasatinib in treating chronic lymphocytic leukemia, acute myeloid leukemia, and myeloproliferative neoplasms [J].

Amrein, Philip C. .

LEUKEMIA & LYMPHOMA, 2011, 52 (05) :754-763

[2] Comparison of FISH and quantitative RT-PCR for the diagnosis and follow-up of BCR-ABL-Positive Leukemias [J].

Bao, Fei ;

Munker, Reinhold ;

Lowery, Clarissa ;

Martin, Sherry ;

Shi, Runhua ;

Veillon, Diana M. ;

Cotelingam, James D. ;

Nordberg, Mary Lowery .

MOLECULAR DIAGNOSIS & THERAPY, 2007, 11 (04) :239-245

[3] Novel Prognostic Gene Mutations Identified in Chronic Lymphocytic Leukemia and Their Impact on Clinical Practice [J].

Campregher, Paulo Vidal ;

Hamerschlak, Nelson .

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2014, 14 (04) :271-276

[4] Chronic lymphocytic leukemia in the course of chronic myelocytic leukemia: evidence of independent clonal origin as shown by interphase fluorescence in situ hybridization and fluorescence-activated cell sorting [J].

Chang, H ;

Sutherland, R ;

Nayar, R ;

Li, D ;

Kamel-Reid, S ;

Mile, MA ;

Messner, H ;

Lipton, J .

CANCER GENETICS AND CYTOGENETICS, 2004, 152 (02) :146-148

[5] Does the immune system naturally protect against cancer? [J].

Corthay, Alexandre .

FRONTIERS IN IMMUNOLOGY, 2014, 5

[6] Chronic Lymphocytic Leukemia After Chronic Myeloid Leukemia in the Same Patient: Two Different Genomic Events and a Common Treatment? [J].

D'Arena, Giovanni ;

Gemei, Marica ;

Luciano, Luigiana ;

D'Auria, Fiorella ;

Deaglio, Silvia ;

Statuto, Teodora ;

Bianchino, Gabriella ;

Grieco, Vitina ;

Mansueto, Giovanna ;

Guariglia, Roberto ;

Pietrantuono, Giuseppe ;

Martorelli, Maria Carmen ;

Villani, Oreste ;

Del Vecchio, Luigi ;

Musto, Pellegrino .

JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (32) :E327-E330

[7] BCR-ABL rearrangement is not detectable in essential thrombocythemia [J].

Emilia, G ;

Marasca, R ;

Zucchini, P ;

Temperani, P ;

Luppi, M ;

Torelli, G ;

Lanza, F ;

De Angelis, C ;

Gandini, D ;

Castoldi, G ;

Vallisa, D ;

Cavanna, L ;

del Senno, L .

BLOOD, 2001, 97 (07) :2187-2189

[8]

Esteve J, 1997, HAEMATOLOGICA, V82, P596

[9] Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates [J].

Filppula, A. M. ;

Laitila, J. ;

Neuvonen, P. J. ;

Backman, J. T. .

BRITISH JOURNAL OF PHARMACOLOGY, 2012, 165 (08) :2787-2798

[10] Lenalidomide maintenance after first-line therapy for high-risk chronic lymphocytic leukaemia (CLLM1): final results from a randomised, double-blind, phase 3 study [J].

Fink, Anna Maria ;

Bahlo, Jasmin ;

Robrecht, Sandra ;

Al-Sawaf, Othman ;

Aldaoud, Ali ;

Hebart, Holger ;

Jentsch-Ullrich, Kathleen ;

Doerfel, Steffen ;

Fischer, Kirsten ;

Wendtner, Clemens-Martin ;

Noesslinger, Thomas ;

Ghia, Paolo ;

Bosch, Francesc ;

Kater, Arnon P. ;

Dohner, Hartmut ;

Kneba, Michael ;

Kreuzer, Karl-Anton ;

Tausch, Eugen ;

Stilgenbauer, Stephan ;

Ritgen, Matthias ;

Boettcher, Sebastian ;

Eichhorst, Barbara ;

Hallek, Michael .

LANCET HAEMATOLOGY, 2017, 4 (10) :E475-E486

← 1 2 3 →